影响治疗决策和坚持前列腺癌积极监测的关键决定因素:系统性审查
Pani Nasseri1,2, Jorien Veldwijk2, Christa Niehot1
1Department of Urology, Erasmus University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.
决定对前列腺癌 (PCa) 进行积极监测的男性权衡风险和益处. 了解影响治疗决策和坚持治疗的因素对于改善吸收和生活质量至关重要.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 在瘤学瘤学.
- 决策科学 决策科学 决策科学
背景情况:
- 积极监测 (AS) 是低风险和中等风险前列腺癌 (PCa) 的一种选择.
- 男人必须平衡AS的危害和益处与积极治疗 (AT).
- 了解影响治疗决策 (TDM) 和遵守AS的因素至关重要.
研究的目的:
- 系统地审查影响AS的TDM因素.
- 识别影响AS协议遵守的因素.
主要方法:
- 按照PRISMA指南进行系统审查.
- 在Medline,Embase和其他数据库中进行全面的文献搜索 (1990-2024年).
- 包括检查TDM和遵守AS/主动监测 (AM) 的研究.
主要成果:
- 由信息,社会支持和避免副作用影响的AS决策.
- 选择AT而不是AS与缺乏信息和对进展的恐惧有关.
- 与生活质量和支持相关的AS的坚持;由于活检负担,不确定性或疾病升级而非坚持.
结论:
- 许多因素影响男性选择PCa的治疗途径.
- 让家人参与共同的决策,并提供详细的AS信息,可以改善AS的吸收.
- 解决心理社会挑战,让家人参与,可以提高AS的坚持.
更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
06:08A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
Published on: March 21, 2025
相关概念视频
Cancer Survival Analysis
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Factors Affecting Drug Response: Overview
